Biogen BIIB RITUXAN — After Second Threshold Date

Similar metrics at other companies

ALKSRISPERDALCONSTA — Collaborative Arrangement Royalty Rate Upon Termination Of Related Agreement

1.3%0.0pp

ZYMERecognition of deferred revenue — Research and development collaborations (note 11)

$0—

ANABAnaptys Bio Generated Anti PD1Jemperli Dostarlimab — Revenue Recognition Milestone Method Contingent

$15M-89.3%

LGNDRylaze — Total revenue and income

$3.22M+3.3%

FCELAdvanced Technologies — Revenue Remaining Performance Obligation

$4.9M-38.0%

ZYMEMilestone revenue — Research and development collaborations

$0-100%

Questions, answered.

What is Biogen's RITUXAN — after second threshold date?

Biogen (BIIB) reported RITUXAN — after second threshold date of 30% in Q1 2026.

How has Biogen's RITUXAN — after second threshold date changed year-over-year?

Biogen's RITUXAN — after second threshold date decreased by 0.0% year-over-year, from 30% to 30%.

What is the long-term trend for Biogen's RITUXAN — after second threshold date?

Over 2 years (2023 to 2025), Biogen's RITUXAN — after second threshold date has grown at a 0.0% compound annual growth rate (CAGR), from 120% to 120%.

What does RITUXAN — after second threshold date mean?

This metric identifies the economic terms governing a collaborative arrangement once a specific secondary performance or time-based threshold has been surpassed. It marks the transition to a final or subsequent stage of the profit-sharing agreement. Understanding this helps investors forecast the long-term margin profile of the product partnership.